Lisa Takagi

Lisa Takagi

Managing Editor

Tokyo, Japan

Lisa provides editorial coverage of all aspects of Japan’s prescription drug market for Scrip and Pink Sheet, including company, market, pricing and regulatory developments, as well as publishing podcast content regularly in the local Japanese language. Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she covered the IT sector for ITmedia Enterprise in Japan. Lisa is bilingual in Japanese and English. She speaks basic French and Mandarin with keen interests in learning new languages. She holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada.

Latest from Lisa Takagi

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

Citeline Japan Awards 2025 - Enter Now!

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Citeline Japan Awards 2025 - Enter Now!

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.